Kuano is aiming to transform the discovery of enzyme inhibitor drugs using a platform that combines quantum transition state simulation and AI led chemistry. Enzyme catalysis occurs via thermodynamically favoured quantum transition states, which represent an attractive conformation for targeting enzyme inhibitors. Kuano’s proprietary in silico approach rapidly simulates the quantum transition state and generates […]
Nuevocor is a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies. The company’s lead programme is an adeno-associated virus (AAV) – based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene. The company also plans to address other untreatable cardiomyopathies using their novel target discovery platform. […]
Cutanos, a spin-off from the Max Planck Society, is developing dermal targeted delivery systems for novel vaccines and immunotherapies. Delivery of antigens to specialised immune cells, called dendritic cells (DCs), is a promising approach to developing innovative vaccines, as well as immunotherapies against cancer and autoimmune diseases. However, there are different subsets of DCs which […]
NeuVasQ is a spin-off company from the University of Brussels aiming to repair neurovascular function in a range of disorders by restoring the integrity of the blood-brain barrier. The blood-brain barrier (BBB) regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in […]
Tribune Therapeutics is a pre-clinical stage biopharmaceutical company developing novel biological drugs to treat patients with fibrotic diseases, including diseases affecting the kidney, lung and liver. Based on research from Håvard Attramadal‘s lab at Oslo University Hospital, Tribune’s medicines target the CCN protein family. The CCN protein family is a group of signalling proteins central […]
xFOREST Therapeutics is a Japanese startup developing a platform for targeting disease-related RNA structures with small molecules. The company’s platform enables the search for highly specific RNA-binders, empowering the rapid and efficient discovery of RNA-targeting drugs. Tens of thousands of RNAs and tens of thousands of compounds from libraries can be analyzed in parallel with […]
Angios is developing new treatments for challenging vascular diseases using the vascular organoid model developed by the company’s founders. The vascular organoids allow the company to model human microvascular complications in the dish and thereby find new pathways associated with disease progression. Diseases affecting blood vessel functionality remain an unresolved global health problem, especially in […]
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® are proprietary therapeutic proteins based on single-domain antibody fragments, with the benefits of conventional antibodies but at 1/10th the size. MoonLake has licensed Merck KGaA’s phase 3-ready drug sonelokimab (M1095) […]
ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung diseases, carried out by company founder and Chief Scientific Officer C. Vivek Lal at University of Alabama at Birmingham. Chronic respiratory illness is associated with lung dysbiosis (abnormal lung microbiome) […]
Alchemab identifies naturally occurring protective antibodies that counter complex diseases, such as cancer and neurodegenerative diseases, by mining the antibody repertoires of individuals who are resistant to or recovered from disease. Alchemab’s approach was developed with support from scientific founders at Oxford University, Johns Hopkins University and Mount Sinai Hospital. The company’s approach starts by […]